BRAF and malignant colon neoplasm: Given the high activity of VLX50 and VLX60 against the colon cancer cell line HCT116, which is KRAS mutated, the activity of these drugs was compared in three pairs of colon cancer cell lines with different KRAS and BRAF mutation status (Figure 2C–2H and Table 1).